Genomic medicine for cancer diagnosis

Associations between genetic polymorphisms in interleukin-10 and hematological oncology: evidence from a meta-analysis

Background: Associations between polymorphisms in interleukin-10 (IL-10) and hematological oncology were already explored by many genetic association studies, with controversial findings. The aim of this meta-analysis was to more comprehensively analyze associations between polymorphisms in IL-10 and hematological oncology by combing the results of all relevant studies.Methods: Eligible articles were searched from Pubmed, Embase, WOS and CNKI. The latest literature searching update was performed on 8 October 2019. We used Review Manager to combine the results of eligible studies.Results: Forty-one articles were included in this meta-analysis. IL-10 rs1800890 polymorphism was found to be significantly associated with hematological oncology under AA vs. TT+TA (recessive comparison, OR = 1.12, 95% CI 1.02-1.24), and rs1800896 polymorphism was also found to be significantly associated with hematological oncology under AA vs. AG+GG (dominant comparison, OR = 0.89, 95% CI 0.83-0.95) in overall combined analyses. In subgroup analyses, we observed positive results for rs1800871 (recessive comparison), rs1800872 (dominant, recessive and allele comparisons), and rs1800896 (dominant and allele comparisons) polymorphisms in the non-Hodgkin's lymphoma (NHL) subgroup. Besides, we also detected positive associations between rs1800872 polymorphism and acute leukemia (AL) (dominant and recessive comparisons) and found significant associations between rs1800896 polymorphism and chronic leukemia (CL) (recessive comparison).Conclusion: In summary, this meta-analysis demonstrated that IL-10 rs1800890, rs1800896, rs1800871 and rs1800872 polymorphisms may confer susceptibility to hematology oncology, especially for NHL.

A meta-analysis of the relationship between paraoxonase 1 polymorphisms and cancer

Some previous studies already explored associations between paraoxonase 1 (PON1) polymorphisms and cancer, with conflicting findings. Here, we aimed to better analyse the relationship between PON1 polymorphisms and cancer in a larger combined population by performing a meta-analysis. We searched PubMed, Embase, and Web of Science for related articles. We calculated odds ratio (OR) and 95% confidence interval (CI) to estimate whether there are genetic associations between PON1 polymorphisms and cancer. Forty studies were included for this meta-analysis. The PON1 rs854560 polymorphism (L55M) was found to be significantly associated with cancer in general population (dominant comparison: p = .04, OR = 0.85, 95%CI 0.73-0.99; recessive comparison: p = .007, OR = 1.27, 95%CI 1.07-1.51; allele comparison: p = 0.02, OR = 0.85, 95%CI 0.75-0.97). Subgroup analyses indicated that the significant findings were mainly driven by the haematological tumours and breast cancer subgroups. We did not observe any positive findings for PON1 rs662 polymorphism (Q192R) in combined analyses. In summary, this meta-analysis proved that PON1 rs854560 polymorphism could be used to identify individual with elevated susceptibility to cancer, especially for haematological tumours and breast cancer.